Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26317076,flow rate,"The chromatographic separation was achieved with Thermo Hypurity C18 column (50 mm × 4.6 mm, 5 μ) using a mobile phase composition containing 0.1% v/v formic acid in water and acetonitrile (30:70, v/v) at a flow rate of 0.4 mL/min.","Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26317076/),[ml] / [min],0.4,2211,DB01098,Rosuvastatin
,26317076,total run time,The total run time was 3.5 min.,"Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26317076/),min,3.5,2212,DB01098,Rosuvastatin
,28892871,emulsification time,"D-optimal mixture design was used for systematic optimization of L-SNEDDS, which exhibited emulsification time of 131s, globule size <100nm and faster drug release rate >80% in 15min.",Formulation by design approach for development of ultrafine self-nanoemulsifying systems of rosuvastatin calcium containing long-chain lipophiles for hyperlipidemia management. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892871/),s,131,2566,DB01098,Rosuvastatin
,12610743,steady-state AUC(0-24),"In subjects with CP-A, and in four of six subjects with CP-B, rosuvastatin steady-state AUC(0-24) and C(max) were similar to subjects with normal hepatic function (geometric mean values 60.7 ng h/ml and 6.02 ng/ml, respectively).",Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[h·ng] / [ml],60.7,3499,DB01098,Rosuvastatin
,12610743,C(max),"In subjects with CP-A, and in four of six subjects with CP-B, rosuvastatin steady-state AUC(0-24) and C(max) were similar to subjects with normal hepatic function (geometric mean values 60.7 ng h/ml and 6.02 ng/ml, respectively).",Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[ng] / [ml],6.02,3500,DB01098,Rosuvastatin
,12610743,AUC(0-24),Two of six subjects with CP-B who had the highest CP scores (i.e. the highest degrees of hepatic impairment) had the highest AUC(0-24) (128 ng h/ml and 242 ng h/ml) and C(max) (23.4 ng/ml and 96.7 ng/ml) values.,Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[h·ng] / [ml],128,3501,DB01098,Rosuvastatin
,12610743,AUC(0-24),Two of six subjects with CP-B who had the highest CP scores (i.e. the highest degrees of hepatic impairment) had the highest AUC(0-24) (128 ng h/ml and 242 ng h/ml) and C(max) (23.4 ng/ml and 96.7 ng/ml) values.,Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[h·ng] / [ml],242,3502,DB01098,Rosuvastatin
,12610743,C(max),Two of six subjects with CP-B who had the highest CP scores (i.e. the highest degrees of hepatic impairment) had the highest AUC(0-24) (128 ng h/ml and 242 ng h/ml) and C(max) (23.4 ng/ml and 96.7 ng/ml) values.,Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[ng] / [ml],23.4,3503,DB01098,Rosuvastatin
,12610743,C(max),Two of six subjects with CP-B who had the highest CP scores (i.e. the highest degrees of hepatic impairment) had the highest AUC(0-24) (128 ng h/ml and 242 ng h/ml) and C(max) (23.4 ng/ml and 96.7 ng/ml) values.,Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[ng] / [ml],96.7,3504,DB01098,Rosuvastatin
,23767355,run time,A run time of 4 min made it possible to determine many plasma samples/day.,Development and validation of a liquid chromatography/ mass spectrometry method for the simultaneous quantitation of rosuvastatin and ezetimibe in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23767355/),min,4,8468,DB01098,Rosuvastatin
,21712498,AUC(0-24 h),The geometric mean AUC(0-24 h) of rosuvastatin increased from 109 to 161 ng·h/mL (P < .005) and C(max) increased 6.7 to 16.3 ng/mL (P < .001) when coadministered with darunavir/ritonavir.,Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21712498/),[h·ng] / [ml],109 to 161,16124,DB01098,Rosuvastatin
,21712498,C(max),The geometric mean AUC(0-24 h) of rosuvastatin increased from 109 to 161 ng·h/mL (P < .005) and C(max) increased 6.7 to 16.3 ng/mL (P < .001) when coadministered with darunavir/ritonavir.,Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21712498/),[ng] / [ml],6.7 to 16.3,16125,DB01098,Rosuvastatin
,21549539,flow rate,The flow rate was 0.4mL/min and the total run time was 6min.,Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ml] / [min],0.4,16760,DB01098,Rosuvastatin
,21549539,total run time,The flow rate was 0.4mL/min and the total run time was 6min.,Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),min,6,16761,DB01098,Rosuvastatin
,21549539,m/z,"The MS/MS ion transitions monitored were m/z 543.3→198.9 and 481.9→258.3 for chamaechromone and rosuvastatin, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),,543.3,16762,DB01098,Rosuvastatin
,21549539,m/z,"The MS/MS ion transitions monitored were m/z 543.3→198.9 and 481.9→258.3 for chamaechromone and rosuvastatin, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),,198.9,16763,DB01098,Rosuvastatin
,21549539,m/z,"The MS/MS ion transitions monitored were m/z 543.3→198.9 and 481.9→258.3 for chamaechromone and rosuvastatin, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),,481.9,16764,DB01098,Rosuvastatin
,21549539,maximum mean concentration in plasma (C(max),"The maximum mean concentration in plasma (C(max), 795.9±14.6ng/L) was achieved at 11.3±0.8h (T(max)) and the area under curve (AUC(0-60)) was 6976.7±1026.9ngh/L.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ng] / [l],795.9,16765,DB01098,Rosuvastatin
,21549539,T(max),"The maximum mean concentration in plasma (C(max), 795.9±14.6ng/L) was achieved at 11.3±0.8h (T(max)) and the area under curve (AUC(0-60)) was 6976.7±1026.9ngh/L.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),h,11.3,16766,DB01098,Rosuvastatin
,21549539,area under curve (AUC(0-60)),"The maximum mean concentration in plasma (C(max), 795.9±14.6ng/L) was achieved at 11.3±0.8h (T(max)) and the area under curve (AUC(0-60)) was 6976.7±1026.9ngh/L.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ngh] / [l],6976.7,16767,DB01098,Rosuvastatin
,21549539,C(max),"After single intravenously administration of chamaechromone, the essential pharmacokinetic parameters C(max), AUC(0-48) were 4300.7±113.6ng/L and 3672.1±225.4ngh/L, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ng] / [l],4300.7,16768,DB01098,Rosuvastatin
,21549539,AUC(0-48),"After single intravenously administration of chamaechromone, the essential pharmacokinetic parameters C(max), AUC(0-48) were 4300.7±113.6ng/L and 3672.1±225.4ngh/L, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ngh] / [l],3672.1,16769,DB01098,Rosuvastatin
,21549539,absolute bioavailability,The result showed that the compound was poorly absorbed with an absolute bioavailability being approximately 8.9%.,Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),%,8.9,16770,DB01098,Rosuvastatin
,29701749,total runtime,Polarity switch (negative-positive-negative ionization mode) was performed in a total runtime of 5.0 min.,"Simultaneous determination of rosuvastatin, naringin and naringenin in rat plasma by RRLC-MS/MS and its application to a pharmacokinetic drug interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29701749/),min,5.0,18963,DB01098,Rosuvastatin
,29692602,steady-state ratios,"In the case of free and total ezetimibe, the steady-state ratios of AUCτ,ss and concentration at steady-state were 1.131 (1.051-1.218) and 1.182 (1.038-1.346), and 1.055 (0.969-1.148) and 0.996 (0.873-1.135), respectively.","Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. ",Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29692602/),,1,20157,DB01098,Rosuvastatin
,16838266,flow gradient,"The chromatographic run time was less than 20 min using flow gradient (0.0-1.60 mL/min) with a mobile phase consisting of 0.01 M ammonium acetate:acetonitrile:methanol (50:40:10, v/v/v) and UV detection at 275 nm.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),[ml] / [min],0.0-1.60,22411,DB01098,Rosuvastatin
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,6.7,22412,DB01098,Rosuvastatin
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,13.9,22413,DB01098,Rosuvastatin
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,16.4,22414,DB01098,Rosuvastatin
greater,16838266,Absolute recovery,Absolute recovery of both analytes and IS was greater than 90%.,Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),%,90,22415,DB01098,Rosuvastatin
,17568401,area under the concentration-time curve for 0 to infinity (AUC(0-infinity)),"The area under the concentration-time curve for 0 to infinity (AUC(0-infinity)) of rosuvastatin for group 1 (*1a/*1a, *1a/*1b, *1b/*1b), group 2 (*1a/*15, *1b/*15), and group 3 (*15/*15) were 111+/-49.3, 126+/-45.2, and 191+/-31.0 ng h/ml, respectively, with significant differences among the three groups (P=0.0429) and between *15/*15 and the other groups (P=0.0181).",Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568401/),[h·ng] / [ml],111,22860,DB01098,Rosuvastatin
,17568401,area under the concentration-time curve for 0 to infinity (AUC(0-infinity)),"The area under the concentration-time curve for 0 to infinity (AUC(0-infinity)) of rosuvastatin for group 1 (*1a/*1a, *1a/*1b, *1b/*1b), group 2 (*1a/*15, *1b/*15), and group 3 (*15/*15) were 111+/-49.3, 126+/-45.2, and 191+/-31.0 ng h/ml, respectively, with significant differences among the three groups (P=0.0429) and between *15/*15 and the other groups (P=0.0181).",Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568401/),[h·ng] / [ml],126,22861,DB01098,Rosuvastatin
,17568401,area under the concentration-time curve for 0 to infinity (AUC(0-infinity)),"The area under the concentration-time curve for 0 to infinity (AUC(0-infinity)) of rosuvastatin for group 1 (*1a/*1a, *1a/*1b, *1b/*1b), group 2 (*1a/*15, *1b/*15), and group 3 (*15/*15) were 111+/-49.3, 126+/-45.2, and 191+/-31.0 ng h/ml, respectively, with significant differences among the three groups (P=0.0429) and between *15/*15 and the other groups (P=0.0181).",Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568401/),[h·ng] / [ml],191,22862,DB01098,Rosuvastatin
,19954720,plasma concentration peaked (Cmax),"Rosuvastatin plasma concentration peaked (Cmax) at 3.68 +/- 2.3 ng/ml (geometric mean), 4.5 hours (median; range 2 - 6 hours) after oral dosing.",Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954720/),[ng] / [ml],3.68,24537,DB01098,Rosuvastatin
,19954720,area under the plasma concentration-time from 0 to 48 hours (AUC0-48),The area under the plasma concentration-time from 0 to 48 hours (AUC0-48) was 32.6 +/- 1.6 ng/ml/h.,Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954720/),[ng] / [h·ml],32.6,24538,DB01098,Rosuvastatin
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.33,24850,DB01098,Rosuvastatin
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,2.3,24851,DB01098,Rosuvastatin
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.017,24852,DB01098,Rosuvastatin
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.064,24853,DB01098,Rosuvastatin
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.036,24854,DB01098,Rosuvastatin
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,14,24855,DB01098,Rosuvastatin
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,1.3,24856,DB01098,Rosuvastatin
>,34330719,hepatic extraction ratio,"After the first dose, all statins were rapidly cleared from the circulation (hepatic extraction ratio > 0.7) and excreted into the bile.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,0.7,26059,DB01098,Rosuvastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,7.2,26060,DB01098,Rosuvastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,3.1,26061,DB01098,Rosuvastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,2.6,26062,DB01098,Rosuvastatin
,12942850,elimination half-life,"It is mainly eliminated in the faeces, with an elimination half-life in humans of between 13 and 21 hours.","[Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942850/),h,13 and 21,26698,DB01098,Rosuvastatin
,24683247,steady-state Cmax,The mean (SD) steady-state Cmax was significantly greater after ro-suvastatin administration in the 20-mg group compared with the 5-mg group (37.69 [29.83] vs 6.17 [6.03] ng/mL; P = 0.04).,"Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683247/),[ng] / [ml],37.69,28375,DB01098,Rosuvastatin
,24683247,steady-state Cmax,The mean (SD) steady-state Cmax was significantly greater after ro-suvastatin administration in the 20-mg group compared with the 5-mg group (37.69 [29.83] vs 6.17 [6.03] ng/mL; P = 0.04).,"Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683247/),[ng] / [ml],6.17,28376,DB01098,Rosuvastatin
,24683247,t1/2,The t1/2 was significantly greater in the 20-mg group (15.51 [6.43] hours) compared with the 5-mg group (5.65 [5.08] hours; P = 0.001) and the 10-mg group (8.58 [5.17] hours; P = 0.002).,"Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683247/),h,15.51,28377,DB01098,Rosuvastatin
,24683247,t1/2,The t1/2 was significantly greater in the 20-mg group (15.51 [6.43] hours) compared with the 5-mg group (5.65 [5.08] hours; P = 0.001) and the 10-mg group (8.58 [5.17] hours; P = 0.002).,"Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683247/),h,5.65,28378,DB01098,Rosuvastatin
,24683247,t1/2,The t1/2 was significantly greater in the 20-mg group (15.51 [6.43] hours) compared with the 5-mg group (5.65 [5.08] hours; P = 0.001) and the 10-mg group (8.58 [5.17] hours; P = 0.002).,"Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683247/),h,8.58,28379,DB01098,Rosuvastatin
,24683247,AUC0-t,The mean AUC0-t was significantly greater in the 20-mg group compared with the 5-mg group (349.16 [257.20] vs 40.63 [39.31] ng/mL/h; P = 0.02).,"Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683247/),[ng] / [h·ml],349.16,28380,DB01098,Rosuvastatin
,24683247,AUC0-t,The mean AUC0-t was significantly greater in the 20-mg group compared with the 5-mg group (349.16 [257.20] vs 40.63 [39.31] ng/mL/h; P = 0.02).,"Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683247/),[ng] / [h·ml],40.63,28381,DB01098,Rosuvastatin
,18937306,total chromatographic run time,The total chromatographic run time of 4 min for each sample made it possible to analyze more than 250 human plasma samples per day.,"Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937306/),min,4,28782,DB01098,Rosuvastatin
,18018771,C(min),"Median (interquartile range) rosuvastatin C(min) for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18018771/),[ng] / [ml],0.97,32826,DB01098,Rosuvastatin
,18018771,C(min),"Median (interquartile range) rosuvastatin C(min) for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18018771/),[ng] / [ml],2.5,32827,DB01098,Rosuvastatin
,18018771,C(min),"Median (interquartile range) rosuvastatin C(min) for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18018771/),[ng] / [ml],5.5,32828,DB01098,Rosuvastatin
,29162214,C<sub>max</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of rosuvastatin were 12.5 ng/mL and 115.6 ng×h/mL for the FDC, and 12.2 ng/mL and 115.1 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[ng] / [ml],12.5,33125,DB01098,Rosuvastatin
,29162214,C<sub>max</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of rosuvastatin were 12.5 ng/mL and 115.6 ng×h/mL for the FDC, and 12.2 ng/mL and 115.1 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[ng] / [ml],12.2,33126,DB01098,Rosuvastatin
,29162214,AUC<sub>0-t</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of rosuvastatin were 12.5 ng/mL and 115.6 ng×h/mL for the FDC, and 12.2 ng/mL and 115.1 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[h·ng] / [ml],115.6,33127,DB01098,Rosuvastatin
,29162214,AUC<sub>0-t</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of rosuvastatin were 12.5 ng/mL and 115.6 ng×h/mL for the FDC, and 12.2 ng/mL and 115.1 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[h·ng] / [ml],115.1,33128,DB01098,Rosuvastatin
,29162214,C<sub>max</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of ezetimibe were 4.7 ng/mL and 67.3 ng×h/mL for the FDC, and 4.5 ng/mL and 68.2 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[ng] / [ml],4.7,33129,DB01098,Rosuvastatin
,29162214,C<sub>max</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of ezetimibe were 4.7 ng/mL and 67.3 ng×h/mL for the FDC, and 4.5 ng/mL and 68.2 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[ng] / [ml],4.5,33130,DB01098,Rosuvastatin
,29162214,AUC<sub>0-t</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of ezetimibe were 4.7 ng/mL and 67.3 ng×h/mL for the FDC, and 4.5 ng/mL and 68.2 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[h·ng] / [ml],67.3,33131,DB01098,Rosuvastatin
,29162214,AUC<sub>0-t</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of ezetimibe were 4.7 ng/mL and 67.3 ng×h/mL for the FDC, and 4.5 ng/mL and 68.2 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[h·ng] / [ml],68.2,33132,DB01098,Rosuvastatin
,27810472,oral bioavailability,RC is anti-hyperlipidemic drug with low oral bioavailability (20%) due to first-pass metabolism.,Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27810472/),%,20,33367,DB01098,Rosuvastatin
,27557342,Cmax,"After adjusting for the 421C>A and 521T>C variants, the Cmax in subjects with NR1I2 63396TT wild type were about 2-fold of those of NR1I2 mutant type (63396CC and CT) (10.7 vs. 20.4 ng/mL, P = 0.023), whereas no significant differences were observed for other parameters.","Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557342/),[ng] / [ml],10.7,35849,DB01098,Rosuvastatin
,27557342,Cmax,"After adjusting for the 421C>A and 521T>C variants, the Cmax in subjects with NR1I2 63396TT wild type were about 2-fold of those of NR1I2 mutant type (63396CC and CT) (10.7 vs. 20.4 ng/mL, P = 0.023), whereas no significant differences were observed for other parameters.","Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557342/),[ng] / [ml],20.4,35850,DB01098,Rosuvastatin
,14667956,absolute oral bioavailability,"The absolute oral bioavailability of rosuvastatin was estimated to be 20.1%,and the hepatic extraction ratio was estimated to be 0.63.",Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),%,20.1,42962,DB01098,Rosuvastatin
,14667956,hepatic extraction ratio,"The absolute oral bioavailability of rosuvastatin was estimated to be 20.1%,and the hepatic extraction ratio was estimated to be 0.63.",Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),,0.63,42963,DB01098,Rosuvastatin
,14667956,volume of distribution at steady state,The mean volume of distribution at steady state was 134 L.,Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),l,134,42964,DB01098,Rosuvastatin
,14667956,total plasma clearance,Renal clearance accounted for approximately 28% of total plasma clearance (48.9 L/h).,Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),[l] / [h],48.9,42965,DB01098,Rosuvastatin
,14667956,absolute oral bioavailability,"The absolute oral bioavailability of rosuvastatin in these 10 healthy volunteers was approximately 20%, and absorption was estimated to be 50%.",Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),%,20,42966,DB01098,Rosuvastatin
,14667956,absorption,"The absolute oral bioavailability of rosuvastatin in these 10 healthy volunteers was approximately 20%, and absorption was estimated to be 50%.",Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),%,50,42967,DB01098,Rosuvastatin
,20166442,peak plasma concentration,"Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],9.938,44400,DB01098,Rosuvastatin
,20166442,peak plasma concentration,"Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],28.09,44401,DB01098,Rosuvastatin
,20166442,peak plasma concentration,"Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],43.092,44402,DB01098,Rosuvastatin
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,7.914,44403,DB01098,Rosuvastatin
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,8.445,44404,DB01098,Rosuvastatin
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,15.401,44405,DB01098,Rosuvastatin
,20166442,peak plasma concentration,"A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],9.288,44406,DB01098,Rosuvastatin
,20166442,peak plasma concentration,"A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],18.808,44407,DB01098,Rosuvastatin
,20166442,peak plasma concentration,"A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],49.808,44408,DB01098,Rosuvastatin
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,13.181,44409,DB01098,Rosuvastatin
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,8.035,44410,DB01098,Rosuvastatin
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,15.509,44411,DB01098,Rosuvastatin
,28385543,AUC0-48,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [h·ml],92.5,48581,DB01098,Rosuvastatin
,28385543,AUC0-48,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [h·ml],83.5,48582,DB01098,Rosuvastatin
,28385543,Cmax,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [ml],10.0,48583,DB01098,Rosuvastatin
,28385543,Cmax,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [ml],7.6,48584,DB01098,Rosuvastatin
,29260378,Solubility,"Solubility of RSV in Perilla frutescens oil and Cremophor EL was 25.0 ± 3.0 and 60.0 ± 5.0 mg/mL, respectively.",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[mg] / [ml],25.0,60795,DB01098,Rosuvastatin
,29260378,Solubility,"Solubility of RSV in Perilla frutescens oil and Cremophor EL was 25.0 ± 3.0 and 60.0 ± 5.0 mg/mL, respectively.",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[mg] / [ml],60.0,60796,DB01098,Rosuvastatin
,29260378,viscosity,"Optimized SNES formulation demonstrated particle size of 17.90 nm, dissolution 98.80%, cloud point 45°C, emulsification time 2 min, and viscosity 241.41 ± 5.52 cP.",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),cp,241.41,60797,DB01098,Rosuvastatin
,29260378,C max,"Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0-∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively).",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[ng] / [ml],60.13,60798,DB01098,Rosuvastatin
,29260378,AUC0-∞,"Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0-∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively).",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[h·ng] / [ml],6195,60799,DB01098,Rosuvastatin
,29260378,AUC0-∞,"Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0-∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively).",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[ng] / [ml],284.80,60800,DB01098,Rosuvastatin
,29260378,AUC0-∞,"Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0-∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively).",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[h·ng] / [ml],3131.72,60801,DB01098,Rosuvastatin
,30130726,flow rate,"Separation of AC and rosuvastatin calcium (internal standard, IS) were achieved on a Dikma Leapsil C18 reversed phase column (100 × 2.1 mm, 2.7 μm) with gradient elution using 0.2% (v/v) formic acid in water and acetonitrile as mobile phases, at the flow rate of 0.3 mL/min.",UHPLC-MS/MS method for determination of atorvastatin calcium in human plasma: Application to a pharmacokinetic study based on healthy volunteers with specific genotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30130726/),[ml] / [min],0.3,60920,DB01098,Rosuvastatin
,18674408,apparent oral clearance (CL/F),"For example, apparent oral clearance (CL/F) was estimated to be 257 L/h.","Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18674408/),[l] / [h],257,63182,DB01098,Rosuvastatin
,34396892,IC50,"Phloretin markedly decreased OATP2B1-mediated rosuvastatin uptake, with an IC50 value of 3.6 μM.",In vitro and in vivo evaluation of organic anion-transporting polypeptide 2B1-mediated pharmacokinetic interactions by apple polyphenols. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34396892/),μM,3.6,63706,DB01098,Rosuvastatin
,16470513,absolute recoveries,"The average absolute recoveries of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin and the IS from spiked plasma samples were 54.2 +/- 3.2, 50.1 +/- 3.8, 65.2 +/- 3.6 and 71.7 +/- 2.7%, respectively.",Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),%,54.2,65539,DB01098,Rosuvastatin
,16470513,absolute recoveries,"The average absolute recoveries of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin and the IS from spiked plasma samples were 54.2 +/- 3.2, 50.1 +/- 3.8, 65.2 +/- 3.6 and 71.7 +/- 2.7%, respectively.",Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),%,50.1,65540,DB01098,Rosuvastatin
,16470513,absolute recoveries,"The average absolute recoveries of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin and the IS from spiked plasma samples were 54.2 +/- 3.2, 50.1 +/- 3.8, 65.2 +/- 3.6 and 71.7 +/- 2.7%, respectively.",Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),%,65.2,65541,DB01098,Rosuvastatin
,16470513,absolute recoveries,"The average absolute recoveries of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin and the IS from spiked plasma samples were 54.2 +/- 3.2, 50.1 +/- 3.8, 65.2 +/- 3.6 and 71.7 +/- 2.7%, respectively.",Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),%,71.7,65542,DB01098,Rosuvastatin
,16470513,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),min,2.5,65543,DB01098,Rosuvastatin
,18236139,K (i),"Silymarin inhibited both OATP1B1- and BCRP-mediated rosuvastatin transport in vitro (K (i) 0.93 microM and 97 microM, respectively).",Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18236139/),μM,0.93,67534,DB01098,Rosuvastatin
,18236139,K (i),"Silymarin inhibited both OATP1B1- and BCRP-mediated rosuvastatin transport in vitro (K (i) 0.93 microM and 97 microM, respectively).",Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18236139/),μM,97,67535,DB01098,Rosuvastatin
,27564321,T100%,Hydrophobic carriers as microcrystalline cellulose 102 (MCC) showed superior physical characters and higher dissolution rate over hydrophilic carriers as maltodextrin with respective T100% 30 min and 45 min.,Solid super saturated self-nanoemulsifying drug delivery system (sat-SNEDDS) as a promising alternative to conventional SNEDDS for improvement rosuvastatin calcium oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27564321/),min,30,73371,DB01098,Rosuvastatin
,27564321,T100%,Hydrophobic carriers as microcrystalline cellulose 102 (MCC) showed superior physical characters and higher dissolution rate over hydrophilic carriers as maltodextrin with respective T100% 30 min and 45 min.,Solid super saturated self-nanoemulsifying drug delivery system (sat-SNEDDS) as a promising alternative to conventional SNEDDS for improvement rosuvastatin calcium oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27564321/),min,45,73372,DB01098,Rosuvastatin
,27317801,plasma concentrations,"Average plasma concentrations of CP-I and CP-III prior to drug administration were 0.91 ± 0.21 and 0.15 ± 0.04 nM, respectively, with minimum fluctuation over the three periods.",Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317801/),nM,0.91,73998,DB01098,Rosuvastatin
,27317801,plasma concentrations,"Average plasma concentrations of CP-I and CP-III prior to drug administration were 0.91 ± 0.21 and 0.15 ± 0.04 nM, respectively, with minimum fluctuation over the three periods.",Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317801/),nM,0.15,73999,DB01098,Rosuvastatin
,29643253,uptake Km,"In vitro studies using plated cynomolgus monkey hepatocytes showed active uptake Km values of 2.0 and 3.9 µM for OATP1B probe substrates, pitavastatin and rosuvastatin, respectively.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,2.0,74942,DB01098,Rosuvastatin
,29643253,uptake Km,"In vitro studies using plated cynomolgus monkey hepatocytes showed active uptake Km values of 2.0 and 3.9 µM for OATP1B probe substrates, pitavastatin and rosuvastatin, respectively.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,3.9,74943,DB01098,Rosuvastatin
,29643253,IC50,"Rifampicin inhibited pitavastatin and rosuvastatin active uptake in monkey hepatocytes with IC50 values of 3.0 and 0.54 µM, respectively, following preincubation with the inhibitor.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,3.0,74944,DB01098,Rosuvastatin
,29643253,IC50,"Rifampicin inhibited pitavastatin and rosuvastatin active uptake in monkey hepatocytes with IC50 values of 3.0 and 0.54 µM, respectively, following preincubation with the inhibitor.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,0.54,74945,DB01098,Rosuvastatin
,29643253,IC50,Use of in vitro IC50 obtained following 1 hour preincubation with rifampicin (0.54 µM) predicted correctly the change in mean i.v. clearance and oral exposure of statins as a function of mean unbound maximum plasma concentration of rifampicin.,In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,0.54,74946,DB01098,Rosuvastatin
,18443034,area under the curve (AUC)(0-72),Intake of UDCA led to a significant increase in rosuvastatin area under the curve (AUC)(0-72) from 128.5 ng/ml.h to 182.1 ng/ml.h(P = 0.008) compared with the control group.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[ng] / [h·ml],128.5,76593,DB01098,Rosuvastatin
,18443034,area under the curve (AUC)(0-72),Intake of UDCA led to a significant increase in rosuvastatin area under the curve (AUC)(0-72) from 128.5 ng/ml.h to 182.1 ng/ml.h(P = 0.008) compared with the control group.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[ng] / [h·ml],182.1,76594,DB01098,Rosuvastatin
,18443034,oral clearance,The oral clearance decreased from 155.2 l/h with placebo to 109.8 l/h with UDCA.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[l] / [h],155.2,76595,DB01098,Rosuvastatin
,18443034,oral clearance,The oral clearance decreased from 155.2 l/h with placebo to 109.8 l/h with UDCA.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[l] / [h],109.8,76596,DB01098,Rosuvastatin
,33811848,drug release,"The drug release was found to be 25.8 ± 2.5 and 89.96 ± 2.8 % in five mins, respectively from MTPS and RC-NP formulations.",Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811848/),%,25.8,77200,DB01098,Rosuvastatin
,33811848,drug release,"The drug release was found to be 25.8 ± 2.5 and 89.96 ± 2.8 % in five mins, respectively from MTPS and RC-NP formulations.",Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811848/),%,89.96,77201,DB01098,Rosuvastatin
,33811848,Peff,"The Peff of MTPS and NP of RC was 1.8 ± 0.2 × 10-5 and 2.7 ± 0.3 × 10-5 cm/s, respectively.",Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811848/),[cm] / [s],1.8,77202,DB01098,Rosuvastatin
,33811848,Peff,"The Peff of MTPS and NP of RC was 1.8 ± 0.2 × 10-5 and 2.7 ± 0.3 × 10-5 cm/s, respectively.",Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811848/),[cm] / [s],2.7,77203,DB01098,Rosuvastatin
,29782035,recovery,The recovery for both the analytes and their deuterated internal standards (ISs) ranged from 95.7 to 99.8%.,Simultaneous quantitation of rosuvastatin and ezetimibe in human plasma by LC-MS/MS: Pharmacokinetic study of fixed-dose formulation and separate tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782035/),%,95.7 to 99.8,77859,DB01098,Rosuvastatin
,29782035,resolution factor,The analytes were well resolved with a resolution factor of 3.8.,Simultaneous quantitation of rosuvastatin and ezetimibe in human plasma by LC-MS/MS: Pharmacokinetic study of fixed-dose formulation and separate tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782035/),,3.8,77860,DB01098,Rosuvastatin
,25740267,IC(50),Pradigastat inhibited BCRP-mediated efflux activity in a dose-dependent fashion in a BCRP over-expressing human ovarian cancer cell line with an IC(50) value of 5 μM.,"Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),μM,5,79057,DB01098,Rosuvastatin
,25740267,IC(50),"Similarly, pradigastat inhibited OATP1B1, OATP1B3 (estradiol 17β glucuronide transport), and OAT3 (estrone 3 sulfate transport) activity in a concentrationdependent manner with estimated IC(50) values of 1.66 ± 0.95 μM, 3.34 ± 0.64 μM, and 0.973 ± 0.11 μM, respectively.","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),μM,1.66,79058,DB01098,Rosuvastatin
,25740267,IC(50),"Similarly, pradigastat inhibited OATP1B1, OATP1B3 (estradiol 17β glucuronide transport), and OAT3 (estrone 3 sulfate transport) activity in a concentrationdependent manner with estimated IC(50) values of 1.66 ± 0.95 μM, 3.34 ± 0.64 μM, and 0.973 ± 0.11 μM, respectively.","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),μM,3.34,79059,DB01098,Rosuvastatin
,25740267,IC(50),"Similarly, pradigastat inhibited OATP1B1, OATP1B3 (estradiol 17β glucuronide transport), and OAT3 (estrone 3 sulfate transport) activity in a concentrationdependent manner with estimated IC(50) values of 1.66 ± 0.95 μM, 3.34 ± 0.64 μM, and 0.973 ± 0.11 μM, respectively.","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),μM,0.973,79060,DB01098,Rosuvastatin
,25740267,"AUC(τ, ss)","In the presence of steady state pradigastat concentrations, AUC(τ, ss) of rosuvastatin was unchanged and its Cmax,ss decreased by 14% (5.30 and 4.61 ng/mL when administered alone and coadministered with pradigastat, respectively).","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),[ng] / [ml],5.30,79061,DB01098,Rosuvastatin
,25740267,"AUC(τ, ss)","In the presence of steady state pradigastat concentrations, AUC(τ, ss) of rosuvastatin was unchanged and its Cmax,ss decreased by 14% (5.30 and 4.61 ng/mL when administered alone and coadministered with pradigastat, respectively).","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),[ng] / [ml],4.61,79062,DB01098,Rosuvastatin
,18520949,time to reach Cmax,"Compared to baseline, the area under the plasma concentration-time curve (AUC 0-24h) and maximum plasma concentration (Cmax) of RSV increased by 213% and 600%, respectively, and the time to reach Cmax was shorter (1.75 h vs. 2.91 h) when given with ATV/RTV (P < 0.05).",Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520949/),h,1.75,82303,DB01098,Rosuvastatin
,18520949,time to reach Cmax,"Compared to baseline, the area under the plasma concentration-time curve (AUC 0-24h) and maximum plasma concentration (Cmax) of RSV increased by 213% and 600%, respectively, and the time to reach Cmax was shorter (1.75 h vs. 2.91 h) when given with ATV/RTV (P < 0.05).",Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520949/),h,2.91,82304,DB01098,Rosuvastatin
,28624574,t1/2,"Mean rosuvastatin (standard deviation) t1/2 was similar when rosuvastatin was used concomitantly with ESL and when it was used alone (26.5 [16.3]h, and 22.4 [9.5]h, respectively).",Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28624574/),h,26.5,83834,DB01098,Rosuvastatin
,28624574,t1/2,"Mean rosuvastatin (standard deviation) t1/2 was similar when rosuvastatin was used concomitantly with ESL and when it was used alone (26.5 [16.3]h, and 22.4 [9.5]h, respectively).",Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28624574/),h,22.4,83835,DB01098,Rosuvastatin
not exceeding,29985967,bioavailability,Rosuvastatin calcium (ROSCa) is a poorly soluble drug with bioavailability not exceeding 20%.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),%,20,90559,DB01098,Rosuvastatin
,29985967,zeta potential,The particle size of the leading formula was 461.8 ± 16.68 nm with zeta potential of -31.8 ± 7.22 mV compared to untreated drug that has a particle size of 618μm.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),mv,-,90560,DB01098,Rosuvastatin
,29985967,zeta potential,The particle size of the leading formula was 461.8 ± 16.68 nm with zeta potential of -31.8 ± 7.22 mV compared to untreated drug that has a particle size of 618μm.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),mv,31.8,90561,DB01098,Rosuvastatin
,29985967,Cmax,The in-vivo study of ROSCa from the leading nanoparticle formula showed a significant enhancement in the Cmax after 2 h (82.35 ng/ml) compared to 9.2 ng/ml for untreated drug.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),[ng] / [ml],82.35,90562,DB01098,Rosuvastatin
,29985967,Cmax,The in-vivo study of ROSCa from the leading nanoparticle formula showed a significant enhancement in the Cmax after 2 h (82.35 ng/ml) compared to 9.2 ng/ml for untreated drug.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),[ng] / [ml],9.2,90563,DB01098,Rosuvastatin
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼1.1,92275,DB01098,Rosuvastatin
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.014,92276,DB01098,Rosuvastatin
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼0.3,92277,DB01098,Rosuvastatin
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.007,92278,DB01098,Rosuvastatin
,16389642,flow rate,"Mobile phase consisting of 0.05 m formic acid and acetonitrile (55:45, v/v) was used at a flow rate of 1.0 mL/min for the effective separation of RST and IS.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),[ml] / [min],1.0,94723,DB01098,Rosuvastatin
,16389642,Nominal retention times,"Nominal retention times of RST and IS were 8.6 and 12.5 min, respectively.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),min,8.6,94724,DB01098,Rosuvastatin
,16389642,Nominal retention times,"Nominal retention times of RST and IS were 8.6 and 12.5 min, respectively.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),min,12.5,94725,DB01098,Rosuvastatin
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,85-110,94726,DB01098,Rosuvastatin
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,>,94727,DB01098,Rosuvastatin
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,100,94728,DB01098,Rosuvastatin
,21324753,flow rate,"The method showed adequate separation for rosuvastatin and atorvastatin and best resolution was achieved with Brownlee analytical C18 column (150×4.6 mm, 5 μm) using methanol-water (68:32, v/v; pH adjusted to 3.0 with trifluoroacetic acid) as a mobile phase at a flow rate of 1.5 ml/min and wavelength of 241 nm.","Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21324753/),[ml] / [min],1.5,95580,DB01098,Rosuvastatin
,27668695,C<sub>max,"The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of fimasartan were 258.03 ± 176.75 ng/mL and 746.52 ± 273.49 ng×h/mL for fimasartan alone, and 289.40 ± 231.44 ng/mL and 848.43 ± 267.45 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0. 513 and 0.006, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[ng] / [ml],258.03,97782,DB01098,Rosuvastatin
,27668695,C<sub>max,"The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of fimasartan were 258.03 ± 176.75 ng/mL and 746.52 ± 273.49 ng×h/mL for fimasartan alone, and 289.40 ± 231.44 ng/mL and 848.43 ± 267.45 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0. 513 and 0.006, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[ng] / [ml],289.40,97783,DB01098,Rosuvastatin
,27668695,"AUC<sub>τ,ss</sub>","The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of fimasartan were 258.03 ± 176.75 ng/mL and 746.52 ± 273.49 ng×h/mL for fimasartan alone, and 289.40 ± 231.44 ng/mL and 848.43 ± 267.45 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0. 513 and 0.006, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[h·ng] / [ml],746.52,97784,DB01098,Rosuvastatin
,27668695,"AUC<sub>τ,ss</sub>","The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of fimasartan were 258.03 ± 176.75 ng/mL and 746.52 ± 273.49 ng×h/mL for fimasartan alone, and 289.40 ± 231.44 ng/mL and 848.43 ± 267.45 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0. 513 and 0.006, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[h·ng] / [ml],848.43,97785,DB01098,Rosuvastatin
,27668695,C<sub>max,"The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of rosuvastatin were 9.94 ± 4.48 ng/mL and 85.29 ± 36.25 ng×h/mL for rosuvastatin alone and 11.94 ± 8.47 ng/mL and 77.33 ± 38.71 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0.066 and 0.009, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[ng] / [ml],9.94,97786,DB01098,Rosuvastatin
,27668695,C<sub>max,"The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of rosuvastatin were 9.94 ± 4.48 ng/mL and 85.29 ± 36.25 ng×h/mL for rosuvastatin alone and 11.94 ± 8.47 ng/mL and 77.33 ± 38.71 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0.066 and 0.009, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[ng] / [ml],11.94,97787,DB01098,Rosuvastatin
,27668695,"AUC<sub>τ,ss</sub>","The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of rosuvastatin were 9.94 ± 4.48 ng/mL and 85.29 ± 36.25 ng×h/mL for rosuvastatin alone and 11.94 ± 8.47 ng/mL and 77.33 ± 38.71 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0.066 and 0.009, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[h·ng] / [ml],85.29,97788,DB01098,Rosuvastatin
,27668695,"AUC<sub>τ,ss</sub>","The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of rosuvastatin were 9.94 ± 4.48 ng/mL and 85.29 ± 36.25 ng×h/mL for rosuvastatin alone and 11.94 ± 8.47 ng/mL and 77.33 ± 38.71 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0.066 and 0.009, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[h·ng] / [ml],77.33,97789,DB01098,Rosuvastatin
,15289793,steady,"In transplant recipients taking 10 mg rosuvastatin, geometric mean values and percent coefficient of variation for steady-state AUC(0-24) and Cmax were 284 ng.",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),ng,28,98031,DB01098,Rosuvastatin
,15289793,association constant,"The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L).",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),[μM] / [l],8.5,98032,DB01098,Rosuvastatin
,15289793,50% inhibition constant,"The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L).",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),[μM] / [l],2.2,98033,DB01098,Rosuvastatin
,32453913,half-maximal inhibitory concentration,"In vitro, febuxostat inhibited the ATP-dependent uptake of rosuvastatin into BCRP-overexpressing membrane vesicles with a half-maximal inhibitory concentration of 0.35 µM, whereas allopurinol showed no inhibition with concentrations up to 200 µM.","Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453913/),μM,0.35,102626,DB01098,Rosuvastatin
,21882531,m/z,"Plasma samples were determined with LC-MS: the analyte and internal standard pitavastatin were both analyzed by MS in the ESI, m/z was 480.0 for rosuvastatin and 420.0 for the IS, separately.",[Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882531/),,480.0,108922,DB01098,Rosuvastatin
,21882531,m/z,"Plasma samples were determined with LC-MS: the analyte and internal standard pitavastatin were both analyzed by MS in the ESI, m/z was 480.0 for rosuvastatin and 420.0 for the IS, separately.",[Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882531/),,420.0,108923,DB01098,Rosuvastatin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.90,115460,DB01098,Rosuvastatin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.52,115461,DB01098,Rosuvastatin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.84,115462,DB01098,Rosuvastatin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.01,115463,DB01098,Rosuvastatin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.02,115464,DB01098,Rosuvastatin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.27,115465,DB01098,Rosuvastatin
,20399994,C(max),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],8.33,117127,DB01098,Rosuvastatin
,20399994,C(max),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],10.76,117128,DB01098,Rosuvastatin
,20399994,C(max),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],19.17,117129,DB01098,Rosuvastatin
,20399994,AUC(0-t),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,57.63,117130,DB01098,Rosuvastatin
,20399994,AUC(0-t),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,88.89,117131,DB01098,Rosuvastatin
,20399994,AUC(0-t),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,163.87,117132,DB01098,Rosuvastatin
,20399994,C(max),"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],8.31,117133,DB01098,Rosuvastatin
,20399994,C(max),"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],8.41,117134,DB01098,Rosuvastatin
,20399994,C(max),"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],20.73,117135,DB01098,Rosuvastatin
,20399994,AUC,"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,64.87,117136,DB01098,Rosuvastatin
,20399994,AUC,"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,77.29,117137,DB01098,Rosuvastatin
,20399994,AUC,"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,178.64,117138,DB01098,Rosuvastatin
,20399994,accumulation ratios,"After administration of multiple doses of rosuvastatin 5, 10, and 20 mg, the accumulation ratios were 1.23, 0.95, and 1.23, respectively, indicating minimal accumulation of rosuvastatin.","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),,1.23,117139,DB01098,Rosuvastatin
,20399994,accumulation ratios,"After administration of multiple doses of rosuvastatin 5, 10, and 20 mg, the accumulation ratios were 1.23, 0.95, and 1.23, respectively, indicating minimal accumulation of rosuvastatin.","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),,0.95,117140,DB01098,Rosuvastatin
,33428168,absolute oral availability,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),%,20,118477,DB01098,Rosuvastatin
,33428168,total clearance,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),[l] / [h],28.3,118478,DB01098,Rosuvastatin
,33428168,terminal elimination half-life,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),h,20,118479,DB01098,Rosuvastatin
,33428168,half-life,"The clinical relevance of the statistically significant drug interactions is yet to be investigated following repeated co-administration for at least 15 days, consistent with a half-life of low-density lipoprotein of 3 days.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),d,3,118480,DB01098,Rosuvastatin
,25867662,peak plasma concentration,"For the 10 mg/kg study, the median peak plasma concentration and time to peak plasma concentration were 0.032 μg/mL and 2 hours, respectively.",Plasma Drug Concentrations of Orally Administered Rosuvastatin in Hispaniolan Amazon Parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25867662/),[μg] / [ml],0.032,120957,DB01098,Rosuvastatin
,25867662,time to peak plasma concentration,"For the 10 mg/kg study, the median peak plasma concentration and time to peak plasma concentration were 0.032 μg/mL and 2 hours, respectively.",Plasma Drug Concentrations of Orally Administered Rosuvastatin in Hispaniolan Amazon Parrots (Amazona ventralis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25867662/),h,2,120958,DB01098,Rosuvastatin
,23494963,accumulation ratio,"Little accumulation of rosuvastatin after repeated, once-daily dosing was observed; the geometric mean accumulation ratio for rosuvastatin was 1.37 (coefficient of variation = 36.4 %).",Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494963/),,1.37,123421,DB01098,Rosuvastatin
,29123380,entrapment efficiency,"Formulations (HS1-HS9) have shown entrapment efficiency between 83.50%±0.30% and 88.50%±0.25%, and optimum release was offered by formulation HS7 at both pH levels, ie, 1.2 (89%) and 7.4 (92%).",Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29123380/),%,83.50,126283,DB01098,Rosuvastatin
,29123380,entrapment efficiency,"Formulations (HS1-HS9) have shown entrapment efficiency between 83.50%±0.30% and 88.50%±0.25%, and optimum release was offered by formulation HS7 at both pH levels, ie, 1.2 (89%) and 7.4 (92%).",Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29123380/),%,88.50,126284,DB01098,Rosuvastatin
,29123380,zeta potential,The majority of microparticles had a particle size of less than 500 µm and zeta potential of -37 mV.,Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29123380/),m,37,126285,DB01098,Rosuvastatin
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,243,129954,DB01098,Rosuvastatin
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,553,129955,DB01098,Rosuvastatin
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,15,129956,DB01098,Rosuvastatin
,15116058,inhibition constant,The in vitro results indicate that the maximum gemfibrozil inhibition of rosuvastatin OATP2-mediated uptake was 50%; the inhibition constant for the inhibitory process was 4.0 +/- 1.3 micromol/L.,The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116058/),[μM] / [l],4.0,131878,DB01098,Rosuvastatin
,16841359,flow rate,"The chromatographic separation was performed on an Atlantis C18 column (2.1 mm x 150 mm, 5.0 microm) with a mobile phase consisting of 0.2% formic acid/methanol (30:70, v/v) at a flow rate of 0.20 mL/min.",Quantitative determination of rosuvastatin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16841359/),[ml] / [min],0.20,133213,DB01098,Rosuvastatin
,18193692,recoveries,Sample preparation with this method yielded clean extracts and consistent recoveries: 91.39% for RST and 99.28% for IS.,Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),%,91.39,135206,DB01098,Rosuvastatin
,18193692,recoveries,Sample preparation with this method yielded clean extracts and consistent recoveries: 91.39% for RST and 99.28% for IS.,Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),%,99.28,135207,DB01098,Rosuvastatin
,18193692,total chromatographic run time,"The total chromatographic run time was 3.5 min and the elution of RST and IS occurred at 2.5 and 3.1 min, respectively; this was achieved with a mobile phase consisting of 0.05 mol/L formic acid: acetonitrile (20:80, v/v) at a flow rate of 0.50 ml/min on an Inertsil ODS-3 column (4.6 x 100 mm, 3.0 microm).",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),min,3.5,135208,DB01098,Rosuvastatin
,18193692,flow rate,"The total chromatographic run time was 3.5 min and the elution of RST and IS occurred at 2.5 and 3.1 min, respectively; this was achieved with a mobile phase consisting of 0.05 mol/L formic acid: acetonitrile (20:80, v/v) at a flow rate of 0.50 ml/min on an Inertsil ODS-3 column (4.6 x 100 mm, 3.0 microm).",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),[ml] / [min],0.50,135209,DB01098,Rosuvastatin
,16784736,AUC(0-72),"The AUC(0-72) and AUC(0-infinity) of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group (33.8+/-11.4 vs. 59.6+/-22.2 ng.h/ml, P=0.018; 34.9+/-11.9 vs. 62.2+/-23.5 ng.h/ml, P=0.018), respectively.",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[h·ng] / [ml],33.8,135939,DB01098,Rosuvastatin
,16784736,AUC(0-72),"The AUC(0-72) and AUC(0-infinity) of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group (33.8+/-11.4 vs. 59.6+/-22.2 ng.h/ml, P=0.018; 34.9+/-11.9 vs. 62.2+/-23.5 ng.h/ml, P=0.018), respectively.",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[h·ng] / [ml],59.6,135940,DB01098,Rosuvastatin
,16784736,AUC(0-infinity),"The AUC(0-72) and AUC(0-infinity) of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group (33.8+/-11.4 vs. 59.6+/-22.2 ng.h/ml, P=0.018; 34.9+/-11.9 vs. 62.2+/-23.5 ng.h/ml, P=0.018), respectively.",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[h·ng] / [ml],34.9,135941,DB01098,Rosuvastatin
,16784736,AUC(0-infinity),"The AUC(0-72) and AUC(0-infinity) of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group (33.8+/-11.4 vs. 59.6+/-22.2 ng.h/ml, P=0.018; 34.9+/-11.9 vs. 62.2+/-23.5 ng.h/ml, P=0.018), respectively.",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[h·ng] / [ml],62.2,135942,DB01098,Rosuvastatin
,16784736,C(max),"The C(max) value was higher in the 421CA+421AA group than that in the 421CC group (9.9+/-5.4 vs. 5.1+/-2.4 ng/ml, P=0.048).",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[ng] / [ml],9.9,135943,DB01098,Rosuvastatin
,16784736,C(max),"The C(max) value was higher in the 421CA+421AA group than that in the 421CC group (9.9+/-5.4 vs. 5.1+/-2.4 ng/ml, P=0.048).",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[ng] / [ml],5.1,135944,DB01098,Rosuvastatin
,16784736,CL/F,"The CL/F value was lower in the 421CA+421AA group than that in the 421CC group (384.7+/-161.2 vs. 674.0+/-297.6 l/h, P=0.043).",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[l] / [h],384.7,135945,DB01098,Rosuvastatin
,16784736,CL/F,"The CL/F value was lower in the 421CA+421AA group than that in the 421CC group (384.7+/-161.2 vs. 674.0+/-297.6 l/h, P=0.043).",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[l] / [h],674.0,135946,DB01098,Rosuvastatin
,28685495,relative bioavailability,"The relative bioavailability of rosuvastatin was essentially unchanged when administered with metformin in T1 and T2, but in T3 it increased to 152% for AUC0-tz (90% CI 135-171%) and 154% for C max (90% CI 132-180%).",Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685495/),%,152,136188,DB01098,Rosuvastatin
,28685495,relative bioavailability,"The relative bioavailability of rosuvastatin was essentially unchanged when administered with metformin in T1 and T2, but in T3 it increased to 152% for AUC0-tz (90% CI 135-171%) and 154% for C max (90% CI 132-180%).",Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685495/),%,154,136189,DB01098,Rosuvastatin
,29440178,faa,The faa values obtained on the former assumption were 0.48-0.54.,Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29440178/),,0.48-0.54,141299,DB01098,Rosuvastatin
,28725138,Peff,The optimized Peff ranged 1.44-68.3 × 10-4 cm/s for the drugs under investigation.,Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725138/),[cm] / [s],1.44-68.3 × 10-4,142143,DB01098,Rosuvastatin
,28725138,Saliva/plasma concentrations ratios,Saliva/plasma concentrations ratios ranged 0.17-1.5.,Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725138/),,0.17-1.5,142144,DB01098,Rosuvastatin
,22718749,limit of detection,"Calibration curves were constructed in concentration range of 0.01-20.0 ng/mL and limit of detection and limit of quantification values were found to be 0.68 and 2.30 pg/mL, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[pg] / [ml],0.68,146836,DB01098,Rosuvastatin
,22718749,limit of quantification,"Calibration curves were constructed in concentration range of 0.01-20.0 ng/mL and limit of detection and limit of quantification values were found to be 0.68 and 2.30 pg/mL, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[pg] / [ml],2.30,146837,DB01098,Rosuvastatin
,22718749,maximum plasma concentration,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[ng] / [ml],17.5,146838,DB01098,Rosuvastatin
,22718749,time to reach that concentration,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),h,3.5,146839,DB01098,Rosuvastatin
,22718749,elimination half life,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),h,18.09,146840,DB01098,Rosuvastatin
≈,33704925,absolute bioavailability,"Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of ≈100 mg, with an absolute bioavailability of ≈60%.","Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33704925/),%,60,147401,DB01098,Rosuvastatin
,18042475,C(max),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],10.22,148086,DB01098,Rosuvastatin
,18042475,C(max),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],25.86,148087,DB01098,Rosuvastatin
,18042475,C(max),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],44.99,148088,DB01098,Rosuvastatin
,18042475,T(max),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),h,2.5,148089,DB01098,Rosuvastatin
,18042475,AUC(0-t),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],73.67,148090,DB01098,Rosuvastatin
,18042475,AUC(0-t),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],210.21,148091,DB01098,Rosuvastatin
,18042475,AUC(0-t),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],303.81,148092,DB01098,Rosuvastatin
,18042475,apparent elimination t(1/2),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),h,13.01,148093,DB01098,Rosuvastatin
,18042475,apparent elimination t(1/2),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),h,13.33,148094,DB01098,Rosuvastatin
,18042475,apparent elimination t(1/2),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),h,15.40,148095,DB01098,Rosuvastatin
,18042475,C(max),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],7.57,148096,DB01098,Rosuvastatin
,18042475,C(max),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],20.43,148097,DB01098,Rosuvastatin
,18042475,C(max),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],36.80,148098,DB01098,Rosuvastatin
,18042475,AUC(0-t),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],51.74,148099,DB01098,Rosuvastatin
,18042475,AUC(0-t),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],136.35,148100,DB01098,Rosuvastatin
,18042475,AUC(0-t),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],232.25,148101,DB01098,Rosuvastatin
,18042475,C(max),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],13.40,148102,DB01098,Rosuvastatin
,18042475,C(max),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],32.44,148103,DB01098,Rosuvastatin
,18042475,C(max),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],54.82,148104,DB01098,Rosuvastatin
,18042475,AUC(0-t),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [h·ml],99.99,148105,DB01098,Rosuvastatin
,18042475,AUC(0-t),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [h·ml],298.85,148106,DB01098,Rosuvastatin
,18042475,AUC(0-t),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [h·ml],430.21,148107,DB01098,Rosuvastatin
,18042475,C(max),"However, C(max) and AUC(0-t) values of 0.82 ng/mL and 6.87 ng/mL x h-1, respectively, after oral administration of 10 mg of rosuvastatin in the fed state were significantly different from the corresponding values under fasting conditions (both, P < 0.05).","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],0.82,148108,DB01098,Rosuvastatin
,18042475,AUC(0-t),"However, C(max) and AUC(0-t) values of 0.82 ng/mL and 6.87 ng/mL x h-1, respectively, after oral administration of 10 mg of rosuvastatin in the fed state were significantly different from the corresponding values under fasting conditions (both, P < 0.05).","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [h·ml],6.87,148109,DB01098,Rosuvastatin
,14512129,maximum plasma concentration (C(max)),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[ng] / [ml],3.75,152364,DB01098,Rosuvastatin
,14512129,maximum plasma concentration (C(max)),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[ng] / [ml],6.79,152365,DB01098,Rosuvastatin
,14512129,maximum plasma concentration (C(max)),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[ng] / [ml],10.3,152366,DB01098,Rosuvastatin
,14512129,maximum plasma concentration (C(max)),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[ng] / [ml],30.1,152367,DB01098,Rosuvastatin
,14512129,time to C(max),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),h,5.0,152368,DB01098,Rosuvastatin
,14512129,area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)),"The corresponding geometric mean values for rosuvastatin area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)) were 31.6, 56.8, 98.2, and 268 ng.h/mL.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[h·ng] / [ml],31.6,152369,DB01098,Rosuvastatin
,14512129,area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)),"The corresponding geometric mean values for rosuvastatin area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)) were 31.6, 56.8, 98.2, and 268 ng.h/mL.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[h·ng] / [ml],56.8,152370,DB01098,Rosuvastatin
,14512129,area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)),"The corresponding geometric mean values for rosuvastatin area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)) were 31.6, 56.8, 98.2, and 268 ng.h/mL.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[h·ng] / [ml],98.2,152371,DB01098,Rosuvastatin
,14512129,area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)),"The corresponding geometric mean values for rosuvastatin area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)) were 31.6, 56.8, 98.2, and 268 ng.h/mL.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[h·ng] / [ml],268,152372,DB01098,Rosuvastatin
,31969307,Cmax,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),[ng] / [ml],29.07,153204,DB01098,Rosuvastatin
,31969307,[AUC]xo,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),[ng] / [h·ml],206.65,153205,DB01098,Rosuvastatin
,31969307,CL/F,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),[ml] / [h],3275.26,153206,DB01098,Rosuvastatin
,31969307,Vd,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),ml,19377.23,153207,DB01098,Rosuvastatin
,31969307,tmax,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),h,3.0,153208,DB01098,Rosuvastatin
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB01098,Rosuvastatin
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB01098,Rosuvastatin
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB01098,Rosuvastatin
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,5.19,155201,DB01098,Rosuvastatin
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,3.68,155202,DB01098,Rosuvastatin
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,1.04,155203,DB01098,Rosuvastatin
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,1.08,155204,DB01098,Rosuvastatin
,14693307,peak plasma concentration (C(max)),The geometric mean peak plasma concentration (C(max)) of rosuvastatin was 6.06 ng/mL and was reached at a median of 5 hours after dosing.,"Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693307/),[ng] / [ml],6.06,159222,DB01098,Rosuvastatin
,14693307,absolute bioavailability,"Given the absolute bioavailability (20%) and estimated absorption (approximately 50%) of rosuvastatin, this finding suggests that metabolism is a minor route of clearance for this agent.","Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693307/),%,20,159223,DB01098,Rosuvastatin
,14693307,absorption,"Given the absolute bioavailability (20%) and estimated absorption (approximately 50%) of rosuvastatin, this finding suggests that metabolism is a minor route of clearance for this agent.","Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693307/),%,50,159224,DB01098,Rosuvastatin
,25666686,saliva/plasma concentration ratio,"A correlation coefficient of 0.99 between saliva and plasma concentrations, and a saliva/plasma concentration ratio of 0.175 were observed.",Saliva versus plasma bioequivalence of rusovastatin in humans: validation of class III drugs of the salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666686/),,0.175,161391,DB01098,Rosuvastatin
,29051147,Michaelis-Menten constant,"We initially investigated the active transport of rosuvastatin into PXB cells, and found concentration-dependent uptake with a Michaelis-Menten constant value of 4.0 μmol/l and a Vmax value of 4.63 pmol/min per 106 cells.",Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[μM] / [l],4.0,166789,DB01098,Rosuvastatin
,29051147,Vmax,"We initially investigated the active transport of rosuvastatin into PXB cells, and found concentration-dependent uptake with a Michaelis-Menten constant value of 4.0 μmol/l and a Vmax value of 4.63 pmol/min per 106 cells.",Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[pM] / [106·cells·min],4.63,166790,DB01098,Rosuvastatin
,29051147,IC50,Cyclosporine A inhibited the uptake of rosuvastatin with an IC50 value of 0.21 μmol/l.,Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[μM] / [l],0.21,166791,DB01098,Rosuvastatin
,31181484,flow rate,"The two analytes were extracted from plasma sample using acetonitrile-induced protein precipitation then separated on an Agilent Eclipse Plus ODS (4.6 × 100 mm, 3.5 μm) column by gradient elution using 6 mM ammonium formate/0.1% formic acid and ACN at a flow rate 0.4 mL min-1.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ml] / [min],0.4,167338,DB01098,Rosuvastatin
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,492.1,167339,DB01098,Rosuvastatin
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,206,167340,DB01098,Rosuvastatin
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,482.1,167341,DB01098,Rosuvastatin
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,258.1,167342,DB01098,Rosuvastatin
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,409.2,167343,DB01098,Rosuvastatin
,31181484,detection limits (S/N of 3),"Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ng] / [ml],0.05,167344,DB01098,Rosuvastatin
,31181484,detection limits (S/N of 3),"Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ng] / [ml],0.07,167345,DB01098,Rosuvastatin
,18176327,"area under the concentration time curve (AUC)[0,tau]","Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47.6 ng.h/mL (+/-15.3) and 4.34 ng/mL (+/-1.8), respectively, when given alone versus 98.8 ng.h/mL (+/-65.5) and 20.2 ng/mL (+/-16.9) when combined with lopinavir/ritonavir (P < 0.0001).",Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18176327/),[h·ng] / [ml],47.6,168739,DB01098,Rosuvastatin
,18176327,"area under the concentration time curve (AUC)[0,tau]","Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47.6 ng.h/mL (+/-15.3) and 4.34 ng/mL (+/-1.8), respectively, when given alone versus 98.8 ng.h/mL (+/-65.5) and 20.2 ng/mL (+/-16.9) when combined with lopinavir/ritonavir (P < 0.0001).",Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18176327/),[h·ng] / [ml],98.8,168740,DB01098,Rosuvastatin
,18176327,maximum concentration (Cmax),"Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47.6 ng.h/mL (+/-15.3) and 4.34 ng/mL (+/-1.8), respectively, when given alone versus 98.8 ng.h/mL (+/-65.5) and 20.2 ng/mL (+/-16.9) when combined with lopinavir/ritonavir (P < 0.0001).",Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18176327/),[ng] / [ml],4.34,168741,DB01098,Rosuvastatin
,18176327,maximum concentration (Cmax),"Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47.6 ng.h/mL (+/-15.3) and 4.34 ng/mL (+/-1.8), respectively, when given alone versus 98.8 ng.h/mL (+/-65.5) and 20.2 ng/mL (+/-16.9) when combined with lopinavir/ritonavir (P < 0.0001).",Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18176327/),[ng] / [ml],20.2,168742,DB01098,Rosuvastatin
,30050285,entrapment efficiency,The entrapment efficiency was 84.3%±1.3%.,Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050285/),%,84.3,171552,DB01098,Rosuvastatin
,27186665,particle,"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),nm,150.3,171636,DB01098,Rosuvastatin
,27186665,polydispersity index (PDI),"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,0.175,171637,DB01098,Rosuvastatin
,27186665,zeta potential (ζ),"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,0.175,171638,DB01098,Rosuvastatin
,27186665,entrapment efficiency,"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,0.175,171639,DB01098,Rosuvastatin
,27186665,entrapment efficiency,"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,-,171640,DB01098,Rosuvastatin
,27186665,entrapment efficiency,"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,32.9,171641,DB01098,Rosuvastatin
,16541405,linear dynamic,The assay exhibited a linear dynamic range of 2-500 ng/mL for fluvastatin in human plasma.,Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of fluvastatin in human plasma: validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16541405/),[ng] / [ml],2-500,173102,DB01098,Rosuvastatin
,16541405,run time,A run time of 1.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of fluvastatin in human plasma: validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16541405/),min,1.5,173103,DB01098,Rosuvastatin
,16806856,maximum concentration,"The study showed that there is a substantial and immediate transport of rosuvastatin into the human bile, with the maximum concentration appearing 42 min after dosing, 39,000+/-31,000 ng/ml.",Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806856/),[ng] / [ml],"39,000",175221,DB01098,Rosuvastatin
,16806856,bile to plasma ratio,"At all time points the biliary concentration exceeded the plasma concentration, and the average bile to plasma ratio was 5200+/-9200 (range 89-33,900, median 2000).",Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806856/),,5200,175222,DB01098,Rosuvastatin
,23722358,flow rate,"The mobile phase consisted of a gradient mixture of 15 µmol/L ammonium acetate in water and in methanol, maintained at a flow rate of 0.4 mL/min.",Development and validation of a sensitive method for simultaneous determination of rosuvastatin and N-desmethyl rosuvastatin in human plasma using liquid chromatography/negative electrospray ionization/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722358/),[ml] / [min],0.4,179423,DB01098,Rosuvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,16.0,183649,DB01098,Rosuvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,43.5,183650,DB01098,Rosuvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,15.2,183651,DB01098,Rosuvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,28.4,183652,DB01098,Rosuvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,5.2,183653,DB01098,Rosuvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,6.3,183654,DB01098,Rosuvastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,35,184743,DB01098,Rosuvastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,23,184744,DB01098,Rosuvastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,31,184745,DB01098,Rosuvastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184746,DB01098,Rosuvastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],0.943,184747,DB01098,Rosuvastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184748,DB01098,Rosuvastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,16,184749,DB01098,Rosuvastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],3.39,184750,DB01098,Rosuvastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],5.48,184751,DB01098,Rosuvastatin
,29472495,area under the concentration-time curve to the last sampling time (AUC0-12),"The area under the concentration-time curve to the last sampling time (AUC0-12) values for apixaban were not different between control and NAFLD subjects (671 and 545 ng/ml × hour, respectively; P = 0.15).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],671,185762,DB01098,Rosuvastatin
,29472495,area under the concentration-time curve to the last sampling time (AUC0-12),"The area under the concentration-time curve to the last sampling time (AUC0-12) values for apixaban were not different between control and NAFLD subjects (671 and 545 ng/ml × hour, respectively; P = 0.15).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],545,185763,DB01098,Rosuvastatin
,29472495,AUC0-12,"Similarly, the AUC0-12 values for rosuvastatin did not differ between the control and NAFLD groups (25.4 and 20.1 ng/ml × hour, respectively; P = 0.28).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],25.4,185764,DB01098,Rosuvastatin
,29472495,AUC0-12,"Similarly, the AUC0-12 values for rosuvastatin did not differ between the control and NAFLD groups (25.4 and 20.1 ng/ml × hour, respectively; P = 0.28).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],20.1,185765,DB01098,Rosuvastatin
,27036206,Maximal tolerated dose (MTD),Maximal tolerated dose (MTD) was determined to be 1 mg/kg/day.,A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27036206/),[mg] / [d·kg],1,187610,DB01098,Rosuvastatin
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB01098,Rosuvastatin
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[ng] / [ml],58.2,194741,DB01098,Rosuvastatin
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[ng] / [ml],12.2,194742,DB01098,Rosuvastatin
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[h·ng] / [ml],272.6,194743,DB01098,Rosuvastatin
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[h·ng] / [ml],58.8,194744,DB01098,Rosuvastatin
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[h·ng] / [ml],366.1,194745,DB01098,Rosuvastatin
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[h·ng] / [ml],66.4,194746,DB01098,Rosuvastatin
,16143964,flow rate,"Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),[ml] / [min],1,196690,DB01098,Rosuvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,7.5,196691,DB01098,Rosuvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,17.2,196692,DB01098,Rosuvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,21.6,196693,DB01098,Rosuvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,28.5,196694,DB01098,Rosuvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,33.5,196695,DB01098,Rosuvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,35.5,196696,DB01098,Rosuvastatin
,11772327,plasma half-life,"Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.",Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772327/),h,20,197177,DB01098,Rosuvastatin
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],80.3,199420,DB01098,Rosuvastatin
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],78.5,199421,DB01098,Rosuvastatin
,24521776,AUC0-24,"Mean rosuvastatin AUC0-24 was 157±61.7 ng*h/mL, approximately threefold higher than reported in the literature for nontransplants.",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·ng] / [ml],157,199422,DB01098,Rosuvastatin
,32603512,IC50,"In vitro, daridorexant inhibits BCRP with an IC50 of 3.0 μmol/L.",The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32603512/),[μM] / [l],3.0,202285,DB01098,Rosuvastatin
,23469685,Cmax,"ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24).","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[μg] / [l],11.16,204280,DB01098,Rosuvastatin
,23469685,Cmax,"ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24).","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[μg] / [l],8.35,204281,DB01098,Rosuvastatin
,23469685,AUC(0-infinity),"ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24).","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[h·μg] / [l],86.61,204282,DB01098,Rosuvastatin
,23469685,AUC(0-infinity),"ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24).","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[h·μg] / [l],62.60,204283,DB01098,Rosuvastatin
,23469685,Cmax,"Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers.","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[μg] / [l],12.20,204284,DB01098,Rosuvastatin
,23469685,Cmax,"Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers.","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[μg] / [l],8.70,204285,DB01098,Rosuvastatin
,23469685,AUC(0-infinity),"Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers.","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[h·μg] / [l],98.74,204286,DB01098,Rosuvastatin
,23469685,AUC(0-infinity),"Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers.","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[h·μg] / [l],64.97,204287,DB01098,Rosuvastatin
,19773540,biliary recoveries,"The biliary recoveries of the administered rosuvastatin dose were 9.0 +/- 3.5 and 35.7 +/- 15.6% in TI and TIV, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),%,9.0,206726,DB01098,Rosuvastatin
,19773540,biliary recoveries,"The biliary recoveries of the administered rosuvastatin dose were 9.0 +/- 3.5 and 35.7 +/- 15.6% in TI and TIV, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),%,35.7,206727,DB01098,Rosuvastatin
,19773540,AUC(bile)/AUC(VH) ratio,"Rosuvastatin was highly transported into bile as shown by the median AUC(bile)/AUC(VH) ratio in TI of 1770 (1640-11,300).",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,1770,206728,DB01098,Rosuvastatin
,19773540,hepatic,"However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI, 0.89 +/- 0.06; TII, 0.46 +/- 0.13) and increased the AUC(VP) and AUC(VH) by 1.6- and 9.1-fold, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,0.89,206729,DB01098,Rosuvastatin
,19773540,hepatic,"However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI, 0.89 +/- 0.06; TII, 0.46 +/- 0.13) and increased the AUC(VP) and AUC(VH) by 1.6- and 9.1-fold, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,0.46,206730,DB01098,Rosuvastatin
<,33502651,oral bioavailability,"Rosuvastatin is an efficient antihyperlipidemic agent; however, being a BCS class II molecule, it shows poor oral bioavailability of < 20%.","Oral Bioavailability Improvement of Tailored Rosuvastatin Loaded Niosomal Nanocarriers to Manage Ischemic Heart Disease: Optimization, Ex Vivo and In Vivo Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33502651/),%,20,211513,DB01098,Rosuvastatin
,33502651,relative bioavailability,"The in vivo pharmacokinetic parameters in the rat model confirmed the improvement in the oral bioavailability with optimized rosuvastatin loaded niosomes (relative bioavailability = 2.01) in comparison to the rosuvastatin suspension, due to high surface area of niosomes and its lymphatic uptake via transcellular route.","Oral Bioavailability Improvement of Tailored Rosuvastatin Loaded Niosomal Nanocarriers to Manage Ischemic Heart Disease: Optimization, Ex Vivo and In Vivo Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33502651/),,2.01,211514,DB01098,Rosuvastatin
,25985569,AUC(o-72),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],162.64,213960,DB01098,Rosuvastatin
,25985569,AUC(o-72),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],103.99,213961,DB01098,Rosuvastatin
,25985569,AUC(o-72),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],178.51,213962,DB01098,Rosuvastatin
,25985569,AUC(0 --> ∞),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],103.99,213963,DB01098,Rosuvastatin
,25985569,AUC(0 --> ∞),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],178.51,213964,DB01098,Rosuvastatin
,25985569,AUC(0 --> ∞),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],113.60,213965,DB01098,Rosuvastatin
,25985569,C(max),"In the c.800CT + TT mutant group, the C(max) was about 78% higher than those in c.800CC genotype (14.31 ± 3.63 vs. 8.04 ± 1.72 ng x h/ml, P = 0.004).",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],14.31,213966,DB01098,Rosuvastatin
,25985569,C(max),"In the c.800CT + TT mutant group, the C(max) was about 78% higher than those in c.800CC genotype (14.31 ± 3.63 vs. 8.04 ± 1.72 ng x h/ml, P = 0.004).",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],8.04,213967,DB01098,Rosuvastatin
,25985569,oral clearance (CL/F),"The oral clearance (CL/F) of rosuvastatin in subjects with the c.800CT+TT genotype was only 63% of those in the c.800CC genotype (58.32 ± 12.16 vs. 93.04 ± 20.61 ng x h/ml, P = 0.009).",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],58.32,213968,DB01098,Rosuvastatin
,25985569,oral clearance (CL/F),"The oral clearance (CL/F) of rosuvastatin in subjects with the c.800CT+TT genotype was only 63% of those in the c.800CC genotype (58.32 ± 12.16 vs. 93.04 ± 20.61 ng x h/ml, P = 0.009).",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],93.04,213969,DB01098,Rosuvastatin
,12769127,plasma half-life,"Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.",Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12769127/),h,20,214857,DB01098,Rosuvastatin
,29353349,time to reach maximum plasma concentration,"Daclatasvir undergoes rapid absorption, with a time to reach maximum plasma concentration of 1-2 h and an elimination half-life of ~ 10 to 14 h observed in single-ascending dose studies.",Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29353349/),h,1-2,216239,DB01098,Rosuvastatin
,29353349,elimination half-life,"Daclatasvir undergoes rapid absorption, with a time to reach maximum plasma concentration of 1-2 h and an elimination half-life of ~ 10 to 14 h observed in single-ascending dose studies.",Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29353349/),h,10 to 14,216240,DB01098,Rosuvastatin
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.61,219981,DB01098,Rosuvastatin
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.73,219982,DB01098,Rosuvastatin
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.92,219983,DB01098,Rosuvastatin
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],4.37,219984,DB01098,Rosuvastatin
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],5.14,219985,DB01098,Rosuvastatin
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],3.21,219986,DB01098,Rosuvastatin
,19853420,relative bioavailability,The higher AUC(0-12) for both F2 and F5 reflected high relative bioavailability of 136.2% and 159.9% respectively compared to commercial ACV tablets.,Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),%,136.2,219987,DB01098,Rosuvastatin
,19853420,relative bioavailability,The higher AUC(0-12) for both F2 and F5 reflected high relative bioavailability of 136.2% and 159.9% respectively compared to commercial ACV tablets.,Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),%,159.9,219988,DB01098,Rosuvastatin
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pru,171.4,221656,DB01098,Rosuvastatin
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pru,146.3,221657,DB01098,Rosuvastatin
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pr,173.7,221658,DB01098,Rosuvastatin
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pr,157.3,221659,DB01098,Rosuvastatin
less,24012665,globule size,The globule size of the optimized system was less than 200nm which could be an acceptable nanoemulsion size range.,"Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24012665/),nm,200,224754,DB01098,Rosuvastatin
,24012665,z,The zeta potential of the selected CN 7 SNEDDS formulation (cinnamon oil 30%; labrasol 60%; Capmul MCM C8 10%) was -29.5±0.63 with an average particle size distribution of 122nm.,"Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24012665/),,-,224755,DB01098,Rosuvastatin
,24012665,z,The zeta potential of the selected CN 7 SNEDDS formulation (cinnamon oil 30%; labrasol 60%; Capmul MCM C8 10%) was -29.5±0.63 with an average particle size distribution of 122nm.,"Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24012665/),,29.5,224756,DB01098,Rosuvastatin
,12296991,Excretion of radio,"3. Excretion of radioactivity was 98.0% of the dose in the faeces and 0.4% in the urine up to 168 h after oral administration in the intact rat, and was 55.1% in the bile and 0.5% in the urine up to 48 h post-dosing in the bile duct-cannulated rat.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),%,98.0,224758,DB01098,Rosuvastatin
,12296991,Excretion of radio,"3. Excretion of radioactivity was 98.0% of the dose in the faeces and 0.4% in the urine up to 168 h after oral administration in the intact rat, and was 55.1% in the bile and 0.5% in the urine up to 48 h post-dosing in the bile duct-cannulated rat.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),%,0.4,224759,DB01098,Rosuvastatin
,12296991,Excretion of radio,"3. Excretion of radioactivity was 98.0% of the dose in the faeces and 0.4% in the urine up to 168 h after oral administration in the intact rat, and was 55.1% in the bile and 0.5% in the urine up to 48 h post-dosing in the bile duct-cannulated rat.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),%,55.1,224760,DB01098,Rosuvastatin
,12296991,Excretion of radio,"3. Excretion of radioactivity was 98.0% of the dose in the faeces and 0.4% in the urine up to 168 h after oral administration in the intact rat, and was 55.1% in the bile and 0.5% in the urine up to 48 h post-dosing in the bile duct-cannulated rat.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),%,0.5,224761,DB01098,Rosuvastatin
,12296991,radioactivity concentration ratios,"4. In the tissue distribution study, the concentration of the radioactivity in the liver was markedly higher than those in the other tissues, and the radioactivity concentration ratios of the liver to the plasma were between 8 and 25 up to 48 h after oral administration.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),,8 and 25,224762,DB01098,Rosuvastatin
,21998019,limit of detection,The assay limit of detection was 25 pg ml(-1) and the effective working range at relative standard deviations (RSD) of ≤ 5% was 40-2000 pg ml(-1).,Validated enzyme-linked immunosorbent assay for determination of rosuvastatin in plasma at picogram level. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21998019/),[pg] / [ml],25,226327,DB01098,Rosuvastatin
,21998019,Analytical recovery,Analytical recovery of ROS from spiked plasma was 96.2 - 104.8 ± 2.12 - 5.42%.,Validated enzyme-linked immunosorbent assay for determination of rosuvastatin in plasma at picogram level. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21998019/),%,96.2 - 104.8,226328,DB01098,Rosuvastatin
,19474787,transport ratio,"In MDCKII-ABCG2 cells, atorvastatin transport was increased in the apical direction as compared with vector control cells (transport ratio 1.9 +/- 0.1 vs. 1.1 +/- 0.1).",ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19474787/),,1.9,226634,DB01098,Rosuvastatin
,19474787,transport ratio,"In MDCKII-ABCG2 cells, atorvastatin transport was increased in the apical direction as compared with vector control cells (transport ratio 1.9 +/- 0.1 vs. 1.1 +/- 0.1).",ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19474787/),,1.1,226635,DB01098,Rosuvastatin
,12445025,Cmax,"The Cmax values were 4.58 vs 4.54 ng ml-1, and AUC(0,24 h) values were 40.1 vs 42.7 ng ml-1 h, following morning and evening administration, respectively.","Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445025/),[ng] / [ml],4.58,229847,DB01098,Rosuvastatin
,12445025,Cmax,"The Cmax values were 4.58 vs 4.54 ng ml-1, and AUC(0,24 h) values were 40.1 vs 42.7 ng ml-1 h, following morning and evening administration, respectively.","Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445025/),[ng] / [ml],4.54,229848,DB01098,Rosuvastatin
,12445025,"AUC(0,24 h)","The Cmax values were 4.58 vs 4.54 ng ml-1, and AUC(0,24 h) values were 40.1 vs 42.7 ng ml-1 h, following morning and evening administration, respectively.","Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445025/),[h·ng] / [ml],40.1,229849,DB01098,Rosuvastatin
,12445025,"AUC(0,24 h)","The Cmax values were 4.58 vs 4.54 ng ml-1, and AUC(0,24 h) values were 40.1 vs 42.7 ng ml-1 h, following morning and evening administration, respectively.","Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445025/),[h·ng] / [ml],42.7,229850,DB01098,Rosuvastatin
,29243231,Ki,Estimated rifampicin in vivo unbound OATP Ki (0.13 μM) using CPI data was 2-fold lower relative to rosuvastatin.,Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29243231/),μM,0.13,230892,DB01098,Rosuvastatin
,11256847,terminal half-life,The terminal half-life is approximately 20 hours.,"Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11256847/),h,20,235034,DB01098,Rosuvastatin
,24023367,Km,"Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein).",Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023367/),μM,21,236646,DB01098,Rosuvastatin
,24023367,Vmax,"Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein).",Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023367/),[pM] / [milligram·min],1140,236647,DB01098,Rosuvastatin
,15660968,elimination half-lives,"Lovastatin, pravastatin and simvastatin are derived from fungal metabolites and have elimination half-lives of 1-3 h.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1-3,238379,DB01098,Rosuvastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1,238380,DB01098,Rosuvastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,19,238381,DB01098,Rosuvastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,5,238382,DB01098,Rosuvastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,60,238383,DB01098,Rosuvastatin
,33123800,IC50,Scutellarin inhibited hOATP1B3- and rOATP1B2-mediated rosuvastatin uptake (IC50: 45.54 ± 6.67 μM and 27.58 ± 3.97 μM) in vitro in a concentration-dependent manner.,Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33123800/),μM,45.54,238735,DB01098,Rosuvastatin
,33123800,IC50,Scutellarin inhibited hOATP1B3- and rOATP1B2-mediated rosuvastatin uptake (IC50: 45.54 ± 6.67 μM and 27.58 ± 3.97 μM) in vitro in a concentration-dependent manner.,Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33123800/),μM,27.58,238736,DB01098,Rosuvastatin
,32827673,zeta potential,"The prepared chitosomes illustrated an average particle size of 342.22 ± 2.90 nm, a zeta potential value of +28.87 ± 1.39 mV and a drug entrapment efficiency of 94.59 ± 1.62%.","Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),mv,28.87,243687,DB01098,Rosuvastatin
,32827673,entrapment efficiency,"The prepared chitosomes illustrated an average particle size of 342.22 ± 2.90 nm, a zeta potential value of +28.87 ± 1.39 mV and a drug entrapment efficiency of 94.59 ± 1.62%.","Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),%,94.59,243688,DB01098,Rosuvastatin
,32827673,disintegration time,The developed tablets showed an acceptable quality control characteristics and in vivo disintegration time of 1.48 ± 0.439 min.,"Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),min,1.48,243689,DB01098,Rosuvastatin
more,32827673,relative bioavailability,"The chitosomes based tablets demonstrated higher relative bioavailability by more than 30% and 36% when compared with the corresponding pure rosuvastatin and the marketed drug tablets, respectively.","Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),%,30,243690,DB01098,Rosuvastatin
,32827673,relative bioavailability,"The chitosomes based tablets demonstrated higher relative bioavailability by more than 30% and 36% when compared with the corresponding pure rosuvastatin and the marketed drug tablets, respectively.","Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),%,36,243691,DB01098,Rosuvastatin
,31141832,flow rate,"Adequate separation for both analytes was achieved with a Waters C18 column (250 × 4.6 mm, 5 μm) using acetonitrile-5 mm sodium acetate buffer (70:30, v/v; pH adjusted to 3.5 with acetic acid) as a mobile phase at a flow rate of 1.0 mL/min and wavelength of 254 nm.","A simple, rapid and fully validated HPLC method for simultaneous quantitative bio-analysis of rosuvastatin and candesartan in rat plasma: Application to pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31141832/),[ml] / [min],1.0,246051,DB01098,Rosuvastatin
,31594719,Ki,Atorvastatin showed ATP-dependent transport in BCRP-expressing membrane vesicles and it inhibited rosuvastatin transport with Ki of 6.3 ± 2.9 μM (mean ± SD).,Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31594719/),μM,6.3,246384,DB01098,Rosuvastatin
,27288758,flow rate,"The chromatographic separation was carried out in 15min on a Waters C18 column (150×3.9mm i.d., 4μm) with a mobile phase containing 0.2% formic acid and acetonitrile (1:1, v/v) at a flow rate of 0.4ml/min.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),[ml] / [min],0.4,247793,DB01098,Rosuvastatin
,27288758,m,"The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),,286.1,247794,DB01098,Rosuvastatin
,27288758,m/,"The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),,830.3,247795,DB01098,Rosuvastatin
,27288758,m/z,"The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),,494.2,247796,DB01098,Rosuvastatin
,27288758,m/z,"The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),,369.0,247797,DB01098,Rosuvastatin
above,27288758,recoveries,"The recoveries of PIP, DOX and IS were above 75% and there was no matrix effect.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),%,75,247798,DB01098,Rosuvastatin
,27288758,bioavailability,"At the dose of 3.5mg/kg, the bioavailability of PIP was calculated to be 25.36%.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),%,25.36,247799,DB01098,Rosuvastatin
,31342792,incorporation capacity,The physicochemical studies showed that the RCa/CD complexes were well incorporated into CPNs resulted in nanosized particles (215.22 and 189.13 nm) with homogenous size distribution (PDI: 0.203 and 0.182) with relatively high incorporation capacity (76.11 and 68.18%) for the CPN1 and CPN2 formulations respectively.,"Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),%,76.11,247946,DB01098,Rosuvastatin
,31342792,incorporation capacity,The physicochemical studies showed that the RCa/CD complexes were well incorporated into CPNs resulted in nanosized particles (215.22 and 189.13 nm) with homogenous size distribution (PDI: 0.203 and 0.182) with relatively high incorporation capacity (76.11 and 68.18%) for the CPN1 and CPN2 formulations respectively.,"Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),%,68.18,247947,DB01098,Rosuvastatin
,31342792,Papp,"According to permeability studies, pure RCa had lowest permeability data (3.08 × 10-7 cm⋅s-1 Papp value) while CPNs gained higher permeability data (1.36 × 10-5 and 1.12 × 10-5 cm⋅s-1 Papp values) for the CPN1 and CPN2 formulations respectively.","Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),[cm] / [s],3.08 × 10-7,247948,DB01098,Rosuvastatin
,31342792,Papp,"According to permeability studies, pure RCa had lowest permeability data (3.08 × 10-7 cm⋅s-1 Papp value) while CPNs gained higher permeability data (1.36 × 10-5 and 1.12 × 10-5 cm⋅s-1 Papp values) for the CPN1 and CPN2 formulations respectively.","Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),[cm] / [s],1.36 × 10-5,247949,DB01098,Rosuvastatin
,31342792,Papp,"According to permeability studies, pure RCa had lowest permeability data (3.08 × 10-7 cm⋅s-1 Papp value) while CPNs gained higher permeability data (1.36 × 10-5 and 1.12 × 10-5 cm⋅s-1 Papp values) for the CPN1 and CPN2 formulations respectively.","Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),[cm] / [s],1.12 × 10-5,247950,DB01098,Rosuvastatin
,26888941,IC50,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,295,255854,DB01098,Rosuvastatin
,26888941,KI,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,216,255855,DB01098,Rosuvastatin
,26888941,kinact,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),1/[min],0.0179,255856,DB01098,Rosuvastatin
,26888941,IC50,FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC50 value of 157 ± 1.0μM and was devoid of breast cancer resistance protein inhibition (IC50> 500μM).,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,157,255857,DB01098,Rosuvastatin
>,26888941,IC50,FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC50 value of 157 ± 1.0μM and was devoid of breast cancer resistance protein inhibition (IC50> 500μM).,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,500,255858,DB01098,Rosuvastatin
,26888941,IC50,"In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59μM and 2.47μM, respectively.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,1.59,255859,DB01098,Rosuvastatin
,26888941,IC50,"In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59μM and 2.47μM, respectively.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,2.47,255860,DB01098,Rosuvastatin
,26888941,IC50,"Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50= 2.26μM) and Oatp1b2 (IC50= 4.38μM) transporters, which are responsible for rosuvastatin uptake in rat liver.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,2.26,255861,DB01098,Rosuvastatin
,26888941,IC50,"Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50= 2.26μM) and Oatp1b2 (IC50= 4.38μM) transporters, which are responsible for rosuvastatin uptake in rat liver.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,4.38,255862,DB01098,Rosuvastatin
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],95,256281,DB01098,Rosuvastatin
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],110.4,256282,DB01098,Rosuvastatin
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],115.3,256283,DB01098,Rosuvastatin
,18691987,C(max),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ng] / [ml],18.5,256284,DB01098,Rosuvastatin
,18691987,C(max),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ng] / [ml],16.5,256285,DB01098,Rosuvastatin
,18691987,t(1/2),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h,12.8,256286,DB01098,Rosuvastatin
,18691987,t(1/2),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h,13.3,256287,DB01098,Rosuvastatin
,18691987,oral clearance,The oral clearance of rosuvastatin was not significantly affected by rifampicin pretreatment either (0.4 [0.3] vs 0.3 [0.2] L . h; P = 0.072).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h·l,0.4,256288,DB01098,Rosuvastatin
,18691987,oral clearance,The oral clearance of rosuvastatin was not significantly affected by rifampicin pretreatment either (0.4 [0.3] vs 0.3 [0.2] L . h; P = 0.072).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h·l,0.3,256289,DB01098,Rosuvastatin
,23627065,polydispersity index,Results showed better self-nanoemulsifying ability of systems containing triacetin compared to Transcutol P. SNEDDS formed uni-modal nanoemulsion droplet size distributions with droplet size less than 50 nm and polydispersity index values ranging from 0.127 to 0.275.,Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627065/),,0.127 to 0.275,259057,DB01098,Rosuvastatin
,23627065,IC50,The anticancer effect of rosuvastatin was enhanced when incorporated in SNEDDS (IC50 value decreased from 4 to 3 microg/ml) due to the increase in penetration of SNEDDS inside the cells.,Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627065/),[μg] / [ml],4,259058,DB01098,Rosuvastatin
,23627065,IC50,The anticancer effect of rosuvastatin was enhanced when incorporated in SNEDDS (IC50 value decreased from 4 to 3 microg/ml) due to the increase in penetration of SNEDDS inside the cells.,Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627065/),[μg] / [ml],3,259059,DB01098,Rosuvastatin
,23627065,relative bioavailability,The relative bioavailability for SNEDDS tablets compared to the commercial tablets was 167%.,Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627065/),%,167,259060,DB01098,Rosuvastatin
,32014599,Papp,The SLN2 formulation showed the best cytotoxicity test results and had medium permeability (Papp 5.72 × 10-6 cm sec-1) while pure RCa resulted in low permeability (Papp 3.08 × 10-7 cm sec-1).,Physicochemical characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated solid lipid nanoparticles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014599/),[cm] / [s],5.72 × 10-6,268139,DB01098,Rosuvastatin
,32014599,Papp,The SLN2 formulation showed the best cytotoxicity test results and had medium permeability (Papp 5.72 × 10-6 cm sec-1) while pure RCa resulted in low permeability (Papp 3.08 × 10-7 cm sec-1).,Physicochemical characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated solid lipid nanoparticles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014599/),[cm] / [s],3.08 × 10-7,268140,DB01098,Rosuvastatin
